PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Rain Therapeutics Inc. (RAIN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US75082Q1058

CUSIP

75082Q105

Sector

Healthcare

IPO Date

Apr 23, 2021

Highlights

Market Cap

$44.01M

EPS (TTM)

-$2.07

EBITDA (TTM)

-$3.00M

Target Price

$2.00

Short %

5.03%

Short Ratio

1.90

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
RAIN vs. VOO
Popular comparisons:
RAIN vs. VOO

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Rain Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


RAIN (Rain Therapeutics Inc.)
Benchmark (^GSPC)

Returns By Period


RAIN

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

4.46%

1M

2.46%

6M

9.31%

1Y

23.49%

5Y*

13.03%

10Y*

11.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of RAIN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202312.25%-0.33%-2.35%-19.57%-84.21%8.11%10.83%-21.05%-17.92%24.16%-1.87%14.29%-85.00%
2022-33.39%-30.30%-15.22%-21.70%-41.56%139.66%15.47%-7.63%-17.71%17.21%34.97%3.63%-37.89%
20213.61%21.38%-21.79%7.14%5.29%-14.66%4.14%-16.94%-0.46%-18.48%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Rain Therapeutics Inc. (RAIN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
No data
RAIN
^GSPC

There is not enough data available to calculate the Sharpe ratio for Rain Therapeutics Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio
RAIN (Rain Therapeutics Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Rain Therapeutics Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


RAIN (Rain Therapeutics Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Rain Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Rain Therapeutics Inc. was 96.07%, occurring on Sep 15, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-96.07%Jul 13, 2021549Sep 15, 2023
-23.45%May 28, 202123Jun 30, 20217Jul 12, 202130
-18%May 10, 20214May 13, 20218May 25, 202112
-2.91%Apr 26, 20212Apr 27, 20211Apr 28, 20213
-2.51%May 4, 20213May 6, 20211May 7, 20214

Volatility

Volatility Chart

The current Rain Therapeutics Inc. volatility is 4.14%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


RAIN (Rain Therapeutics Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Rain Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Rain Therapeutics Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab